Scorpius Holdings, Inc. (SCPX)
USD 0.29
(-0.87%)
USD 0.29
(-0.87%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 22.74 Million USD | -28.84% |
| 2022 | 31.96 Million USD | 257.99% |
| 2021 | 8.92 Million USD | 2.61% |
| 2020 | 8.7 Million USD | -78.61% |
| 2019 | 40.66 Million USD | 33.6% |
| 2018 | 30.43 Million USD | 111.26% |
| 2017 | 14.4 Million USD | 600.58% |
| 2016 | 2.05 Million USD | -80.82% |
| 2015 | 10.72 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.24 Million USD | 11.0% |
| 2024 Q2 | 24.82 Million USD | -1.65% |
| 2023 Q1 | 31.17 Million USD | -54.34% |
| 2023 Q4 | 22.74 Million USD | -37.64% |
| 2023 Q3 | 36.46 Million USD | 10.12% |
| 2023 FY | 22.74 Million USD | -28.84% |
| 2023 Q2 | 33.11 Million USD | 6.22% |
| 2022 Q4 | 68.28 Million USD | 84.37% |
| 2022 Q3 | 37.03 Million USD | 1.57% |
| 2022 Q2 | 36.46 Million USD | 281.14% |
| 2022 Q1 | 9.56 Million USD | -70.68% |
| 2022 FY | 31.96 Million USD | 257.99% |
| 2021 Q3 | 8.78 Million USD | 5.68% |
| 2021 FY | 8.92 Million USD | 2.61% |
| 2021 Q2 | 8.31 Million USD | 3.83% |
| 2021 Q4 | 32.62 Million USD | 271.2% |
| 2021 Q1 | 8.01 Million USD | 0.0% |
| 2020 FY | 8.7 Million USD | -78.61% |
| 2019 FY | 40.66 Million USD | 33.6% |
| 2018 FY | 30.43 Million USD | 111.26% |
| 2017 FY | 14.4 Million USD | 600.58% |
| 2016 FY | 2.05 Million USD | -80.82% |
| 2015 FY | 10.72 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -148.642% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -857.209% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 83.987% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 49.533% |
| Azitra, Inc. | 2.2 Million USD | -932.688% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -507.135% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -247.707% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -24.593% |
| CEL-SCI Corporation | 17.31 Million USD | -31.363% |
| iBio, Inc. | 7.41 Million USD | -206.927% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 41.678% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -220.81% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 50.912% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -81.729% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -297.61% |
| NanoViricides, Inc. | 1.35 Million USD | -1573.807% |
| Oragenics, Inc. | 1.79 Million USD | -1164.794% |
| BiomX Inc. | 55.07 Million USD | 58.705% |
| BiomX Inc. | 55.07 Million USD | 58.705% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 55.287% |
| Palatin Technologies, Inc. | 10.85 Million USD | -109.543% |